Status:
COMPLETED
Understanding Immunity Persistence After Adolescent MenC Vaccination
Lead Sponsor:
University of Oxford
Conditions:
Antibody Persistance After Booster Dose of Men C Vaccine
Eligibility:
All Genders
20-23 years
Brief Summary
The main purpose of this study is to evaluate the duration of immunity after a booster dose of a MenC-CRM vaccine given to adolescents between 13 and 15 years of age. Does seroprotection persist beyon...
Eligibility Criteria
Inclusion
- Participants who completed clinical study M14P2E1
- Participant who are willing to participate and who would be expected to comply with the requirements of the protocol
- Participants who have given informed consent for participation in the study
Exclusion
- History of invasive meningococcal C disease (or any case of invasive meningococcal disease where the serotype was unknown)
- Confirmed or suspected immunosuppressive or immunodeficient conditions, including human immunodeficiency virus (HIV) infection
- Severe blood clotting disorders
Key Trial Info
Start Date :
November 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
134 Patients enrolled
Trial Details
Trial ID
NCT01459432
Start Date
November 1 2011
Last Update
November 9 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oxford Vaccine Group
Oxford, United Kingdom, OX3 8NQ